In a prespecified analysis of the FLOW trial, the use of an SGLT2 inhibitor did not impact the overall benefits of semaglutide on kidney and cardiovascular outcomes in participants with type 2 diabetes and chronic kidney disease.
- Johannes F. E. Mann
- Peter Rossing
- Katherine R. Tuttle
